NCT06065722View on ClinicalTrials.gov

Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

PHASE2UnknownINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 9, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Chemotherapy Induced Nausea and Vomiting

Interventions

DRUG

Akynzeo

OLANZAPINE

Trial Locations (1)

35117

RECRUITING

Rudolph M Navari, Mount Olive

Sponsors

Collaborators (1)

Helsinn Healthcare SA

All Listed Sponsors

collaborator

Helsinn Healthcare SA

INDUSTRY

lead

Simon Williamson Clinic

INDUSTRY